These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 17468669

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, González-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutiérrez-Valencia A, Girón-González JA, Macías J, López-Cortés LF, Pineda JA.
    Antivir Ther; 2007 Jan 02; 12(4):523-9. PubMed ID: 17668561
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.
    J Womens Health (Larchmt); 2015 Feb 02; 24(2):159-64. PubMed ID: 25682817
    [Abstract] [Full Text] [Related]

  • 7. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Feb 02; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 8. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276
    [Abstract] [Full Text] [Related]

  • 9. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Feb 01; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V.
    J Viral Hepat; 2008 Oct 01; 15(10):710-5. PubMed ID: 18637070
    [Abstract] [Full Text] [Related]

  • 12. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group.
    Antivir Ther; 2007 Sep 15; 12(4):469-76. PubMed ID: 17668555
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Martín-Carbonero L, Romero M, García-Samaniego J, Soriano V.
    Antivir Ther; 2005 Sep 15; 10(5):657-62. PubMed ID: 16152759
    [Abstract] [Full Text] [Related]

  • 18. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.
    J Manag Care Pharm; 2013 Sep 15; 19(6):448-53. PubMed ID: 23806058
    [Abstract] [Full Text] [Related]

  • 19. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
    Morello J, Soriano V, Barreiro P, Medrano J, Madejón A, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, Rodríguez-Novoa S.
    Antimicrob Agents Chemother; 2010 Apr 15; 54(4):1647-9. PubMed ID: 20100874
    [Abstract] [Full Text] [Related]

  • 20. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA.
    PLoS One; 2015 Apr 15; 10(12):e0143492. PubMed ID: 26640956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.